Compare Mongodb Inc (MDB) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mongodb Inc vs TG Therapeutics Inc — how do they compare? Mongodb Inc trades at $436.61 (market cap $35.32B), while TG Therapeutics Inc trades at $49.44 (market cap $7.64B). The key difference: Mongodb Inc is far larger — about 4.6× TG Therapeutics Inc's market cap, and Mongodb Inc is trading nearer its 52-week high, TG Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| MDB | TGTX | |
|---|---|---|
Market Cap | $35.32B | $7.64B |
Sector | Technology | Health |
52-Week High | $440.25 | $59.06 |
52-Week Low | $204.37 | $26.94 |
Enterprise Value | $32.93B | $7.84B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MDB trades at $436.91, up 4.86% over the past day, with a bullish technical signal from moving averages and strong analyst sentiment. Revenue growth is robust, reaching $2.01B in 2025, though the company remains unprofitable with a net income margin of -1.12%. Recent earnings beats and an upcoming Q2 2026 report on September 1, 2026, highlight operational momentum amid high institutional interest.
The outlook is positive given consistent earnings outperformance and projected revenue growth to $2.6B in 2026. Risks include persistent losses, competitive pressures, and high valuation multiples. With 82% of analysts rating it a buy and a consensus price target of $404.30, the stock offers growth potential but requires monitoring of profitability trends.
TG Therapeutics (TGTX) trades at $49.50, up 0.69% today, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong revenue growth, with Q2 2026 sales reaching $240 million and raised full-year guidance to $950 million, though it missed earnings estimates for three consecutive quarters. Profitability metrics remain robust with a net income margin of 55.22% and ROE exceeding 100%, but valuation ratios like EV/EBITDA at 56.26 suggest premium pricing.
The outlook is mixed: bullish analyst sentiment with an 84.6% buy rating and a $63.75 price target offers upside potential, driven by Briumvi's commercial success and expansion into schizophrenia trials. However, risks include earnings misses, a shareholder investigation into fiduciary duties, and high cash burn in 2025. Investors should weigh strong revenue momentum against execution risks and elevated valuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Mongodb Inc
Founded in 2007, MongoDB is a document-oriented database with nearly 33,000 paying customers and well past 1.5 million free users. MongoDB provides both licenses as well as subscriptions as a service for its NoSQL database. MongoDB's database is compatible with all major programming languages and is capable of being deployed for a variety of use cases.
Read more on MDB →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
